Search

Displaying results 181 - 190 of 3732 in total
  1. Pathway

    Activation of PKC Through G Protein-Coupled Receptor

    smpdb.ca/view/SMP0000749
    Signaling

    IP3 can bind Ins3P receptor to open calcium channel by diffusion from cytoplasm to ER. Activated calcium channel will release the calcium from ER into cytoplasm.

    Drugs: Calcium
    Enzymes: Inositol 1,4,5-trisphosphate receptor type 1
  2. Pathway

    Intracellular Signalling Through PGD2 receptor and Prostaglandin D2

    smpdb.ca/view/SMP0000343
    Signaling

    The PGD receptor activates G(s) proteins which lead to the activation of adenylyl cyclase which produces the secondary messenger cAMP. cAMP activates PKA (protein kinase A) which phosphorylates downstream

    Drugs: ATP · Magnesium cation · Prostaglandin D2 · Cyclic adenosine monophosphate · Pyrophosphoric acid
    Enzymes: Prostaglandin D2 receptor
  3. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
  4. Drug

    Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine

    go.drugbank.com/drugs/DB16431
    Experimental

    Regarding this vaccine specifically, it stimulates the immune system to produce anti-receptor binding domain antibodies[A226593]. … Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated

  5. Drug

    Mapatumumab

    go.drugbank.com/drugs/DB18945
    Investigational

    Mapatumumab is under investigation in clinical trial NCT00094848 (Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-hodgkin's Lymphoma (NHL)).

    Synonyms: Immunoglobulin g1, anti-(human cytokine receptor dr4 (death receptor 4)) (human monoclonal trm-1 heavy chain), disulfide with human monoclonal trm-1 .lambda.-chain, dimer, Immunoglobulin g1, anti-(human cytokine receptor dr4 (death receceptor 4)) (human monoclonal trm-1 heavy chain), disulfide with human monoclonal trm-1 .lambda.-chain, dimer
  6. Drug

    Barecetamab

    go.drugbank.com/drugs/DB17479
    Investigational

    Synonyms: Immunoglobulin g1, anti-(human epidermal growth factor receptor her3) (human monoclonal isu104 .gamma.1-chain), disulfide with human monoclonal isu104 .lambda.-chain, dimer
  7. Drug

    DF-1001

    go.drugbank.com/drugs/DB18231
    Investigational

    Synonyms: Heterodimeric multi-specific IgG1 antibody targeting human epidermal growth factor receptor 2 (HER2) and NKG2D on natural killer (NK) and cytotoxic T-cells
  8. Drug

    Tomaralimab

    go.drugbank.com/drugs/DB15415
    Investigational

    Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).

    Synonyms: Humanized IGG4 monoclonal antibody against toll-like receptor 2 for prevention of ischemia/reperfusion tissue injury
  9. Drug

    Carboxymethylcellulose

    go.drugbank.com/drugs/DB11059
    ApprovedInvestigational

    Carboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. It is added in food products as a viscosity modifier or t...

    Mixtures: Refresh Digital PF, Refresh RELIEVA PFProducts: FREEGEN PF
  10. Drug

    Etevritamab

    go.drugbank.com/drugs/DB17211
    Investigational

    Synonyms: IMMUNOGLOBULIN SCFV-SCFV, ANTI-(HOMO SAPIENS EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1, ERBB1, HER1, HER-1, ERBB) VARIANT III (EGFRVIII)) AND ANTI-(HOMO SAPIENS CD3E, IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III) (HUMAN MONOCLONAL EGFRVIII BISPECIFIC 1 SINGLE-CHAIN VARIABLE FRAGMENT VH1-(GGGGS)3-VL1) FUSION PROTEIN WITH PEPTIDE